5 research outputs found
Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer
Gross cystic disease fluid protein (GCDFP-
15) and mammaglobin are both widely used and
accepted markers for epithelia of breast origin. We
aimed to evaluate their relation of expression on parallel
whole tissue sections in primary breast cancer by
immunohistochemistry and also to correlate it with
clinico-pathological parameters including patient
survival. Primary breast carcinomas from 165 patients
with a mean clinical follow-up of 73 months were
immunostained using commercially available antibodies
against GCDFP-15 and mammaglobin. An immunoreactive
score (IRS) was calculated based on the
cytoplasmic staining intensity and the number of cells
stained. Cytoplasmic expression of GCDFP-15 and
mammaglobin was observed in 73.3% and 72.1% of
invasive breast carcinomas respectively. 91.8% of breast
cancer cases expressed at least one of both markers.
Both markers strongly correlated with each other and
were significantly associated with lower tumour grading.
Additionally, GCDFP-15 negativity was significantly
associated with shortened disease-free survival times in
univariate and multivariate analyses. We demonstrated
the strong correlation of GCDFP-15 and mammaglobin
with each other and showed that only very few primary
breast cancers are completely negative for both markers.
The significantly longer disease free survival times for
patients with GCDFP-15 positive tumours clearly
warrants further study
A defined chromosome 6q fragment (at D6S310) harbors a putative tumor suppressor gene for breast cancer
Recent evidence obtained by cytogenetic and molecular studies indicates that in breast cancer chromosome 6q is often affected by genetic changes suggesting the existence of putative tumor suppressor genes (TSGs). However the function of gene(s) on this chromosome in breast cancer suppression is not understood. To substantiate further the presence of breast cancer related TSGs at 6q and to define their location, we first performed microcell-mediated transfer of chromosome 6 to CAL51 breast cancer cells for studying possible suppression of malignant phenotype and secondly, we analysed DNAs from 46 primary breast cancers for loss of constitutive heterozygosity (LOH) using 24 poly-morphic microsatellite markers. The chromosome transfer resulted in loss of tumorigenicity and reversion of other neoplastic properties of the microcell hybrids. Polymorphism analysis of single hybrids revealed that they harbored only a small donor chromosome fragment defined by the marker D6S310 (6q23.3-q25) and flanked by D6S292 and D6S311. The LOH data suggest that four tumor suppressor gene loci mapped to the central and distal portion of 6q may be independently deleted in breast cancer. One of these regions corresponds to the region identified by chromosome transfer